我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

半夏泻心汤加减治疗胃食管反流病的Meta分析和试验序贯分析(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2020年05期
页码:
28-35
栏目:
临床研究
出版日期:
2020-12-30

文章信息/Info

Title:
Meta-analysis and Trial Sequential Analysis of Modified Banxia Xiexin Decoctionin the Treatment of Gastroesophageal Reflux Disease
文章编号:
1000-2723(2020)05-0028-08
作者:
俞赟丰兰晓栋金梦雨徐思琦梁妍简维雄△
湖南中医药大学,湖南 长沙 410208
Author(s):
YU Yunfeng LAN Xiaodong JIN Mengyu XU Siqi LIANG Yan JIAN Weixiong
Hunan University of Chinese Medicine, Changsha 410208, China
关键词:
半夏泻心汤质子泵抑制剂促动力药胃食管反流病Meta分析试验序贯分析
Keywords:
Banxia Xiexin Decoction proton pump inhibitor prokinetic drugs gastroesophageal reflux disease Meta-analysis trial sequential analysis
分类号:
R259
DOI:
10.19288/j.cnki.issn.1000-2723.2020.05.006
文献标识码:
A
摘要:
目的〓系统评价半夏泻心汤治疗胃食管反流病(GERD)的有效性,为辨治处方提供临床证据。方法 检索CNKI、VIP、WanFang、PubMed、Embase、The Cochrane Library数据库,查找国内外公开发表的关于半夏泻心汤治疗胃食管反流病的临床研究,由2位研究人员按照纳入与排除标准独立筛选文献,提取资料并评价纳入研究的质量,采用Revman5.3软件进行Meta分析,TSA0.9软件进行试验序贯分析,Stata15.0软件进行发表偏倚评估, GRADE3.6软件进行证据质量评价。结果 共纳入13项研究,共计患者1 089例,其中试验组576例,对照组513例。(1)Meta分析结果显示:同常规西药相比半夏泻心汤能有效提高临床治愈率[RR=1.55,95%CI=(1.17,2.05),P=0.002]、胃镜治愈率[RR=1.45,95%CI=(1.07,1.98),P=0.02]、临床总有效率[RR=1.15,95%CI=(1.10,1.21),P<0.000 01]和胃镜总有效率[RR=1.21,95%CI=(1.09,1.35),P=0.000 3],降低复发率[RR=0.25,95%CI=(0.09,0.72),P=0.01]。(2)试验序贯分析:临床总有效率的累计Z值在第5项研究穿过传统界值和TSA界值,校正后结果一致,可作为确切证据。(3)发表偏倚:Harbord检验显示不存在显著发表偏倚(P=0.12)。(4)证据质量评价:临床治愈率、胃镜治愈率、临床总有效率、胃镜总有效率、复发率的证据质量均为中,推荐强度均为弱推荐。结论 半夏泻心汤应用于胃食管反流病的临床疗效优于优选西药组合,具有在GERD的临床辨治中推广应用的价值。
Abstract:
Objective To systematically evaluate the effectiveness of Banxia Xiexin Decoction in the treatment of gastroesophageal reflux disease (GERD), and to provide clinical evidence for the diagnosis and treatment of prescriptions. Methods Search the databases of CNKI, VIP, WanFang, PubMed, Embase, The Cochrane Library, and search for the treatment of Banxia Xiexin Decoction published at home and abroad. Two researchers independently screened the literature according to the inclusion and exclusion criteria, extracted the data and evaluated the inclusion for the quality of the study, Revman5.3 software was used for Meta-analysis, TSA0.9 software was used for trial sequential analysis, Stata15.0 software was used for publication bias evaluation, and GRADE3.6 software was used for evidence quality evaluation. Results A total of 13 studies were included, with a total of 1089 patients. In fact, there were 576 cases in the test group and 513 cases in the control group. (1) The results of Meta-analysis show that Banxia Xiexin Decoction can effectively improve the clinical cure rate [RR=1.55, 95%CI=(1.17, 2.05), P=0.002] and the cure rate of gastroscopy [RR=1.45, 95%CI=(1.07, 1.98), P=0.02], total clinical effective rate[RR=1.15, 95%CI=(1.10, 1.21), P<0.000 01] and total effective rate of gastroscopy[RR=1.21, 95%CI=(1.09, 1.35), P=0.000 3], reduce the recurrence rate[RR=0.25, 95%CI=(0.09, 0.72), P=0.01]. (2) Trial sequential analysis: The cumulative Z value of the clinical total effective rate crossed the traditional boundary value and the TSA boundary value in the fifth study, and the corrected results are consistent, which can be used as definite evidence. (3) Publication bias: Harbord test showed that there was no significant publication bias(P=0.12). (4) Evidence quality evaluation: The quality of evidence for clinical cure rate, gastroscopy cure rate, clinical total effective rate, total gastroscopy effective rate, and recurrence rate are all medium, and the recommendation strength is weak recommendation. Conclusion The clinical efficacy of Banxia Xiexin Decoction applied to gastroesophageal reflux disease is better than the optimal combination of western medicine, and it has the value of promotion and application in the clinical diagnosis and treatment of GERD.

参考文献/References

[1] 陆星华,张泰昌. 反流性食管炎诊断及治疗指南(2003年)[J]. 中华消化内镜杂志,2004(4):4-5.
[2] CASTELL D O,MURRAY J A,TUTUIAN R,et al. Review article:the pathophysiology of gastro-oesophageal reflux disease-oesophageal manifestations[J]. Aliment Pharmacol Ther,2004,20(Suppl 9):14-25.
[3] VAKIL N,VAN ZANTEN S V,KAHRILAS P,et al. The Montreal definition and classification of gastroesophageal reflux disease:a global evidence-based consensus[J]. Am J Gastroenterol,2006,101(8):1900-1920.
[4] 季锋,汪忠镐. 2013美国胃肠病学院胃食管反流病诊断和管理指南解读[J]. 中华胃食管反流病电子杂志,2015,2(2):70-74.
[5] DEVAULT K R,CASTELL D O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease[J]. Am J Gastroenterol,2005,100(1):190-200.
[6] ARMSTRONG D,MARSHALL J K,CHIBA N,et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004[J]. Can J Gastroenterol,2005,19(1):15-35.
[7] PLAYFORD R J. New British Society of Gastroenterology(BSG)guidelines for the diagnosis and management of Barrett’s oesophagus[J]. Gut,2006,55(4):442.
[8] FOCK K M, TALLEY N, HUNT R, et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease[J]. J Gastroenterol Hepatol,2004, 19(4):357-367.
[9] 刘萱,彭晓霞,于中麟,等. 艾司奥美拉唑治疗胃-食管反流病的荟萃分析[J]. 中国新药与临床杂志,2007(1):40-44.
[10] 曹迎风,李军茹,齐洪军. 经验方联合西药治疗反流性食管炎的临床观察[J]. 中国民间疗法,2019,27(9):81-82.
[11] 付振灿. 西药联合疏和平逆汤治疗反流性食管炎46例临床观察[J]. 中国民族民间医药,2019,28(6):87-88.
[12] 张永智. 疏和平逆汤联合西药治疗反流性食管炎的效果[J]. 河南医学研究,2019,28(18):3390-3391.
[13] 郭瑞萍. 旋复代赭汤合四逆散加味治疗胆汁反流性胃炎临床观察[J]. 新中医,2016,48(10):63-64.
[14] 陈家坤,韦汉鹃,谢胜. 半夏泻心汤治疗胃食管反流病临床研究Meta分析[J]. 亚太传统医药,2017,13(3):53-56.
[15] 齐豫,万晓刚. 半夏泻心汤加减治疗与西药治疗反流性食管炎疗效对比的Meta分析[J]. 湖南中医杂志,2016, 32(10):158-161.
[16] 郑敏,唐艳萍. 半夏泻心汤为主治疗反流性食管炎的Meta分析[J]. 世界中西医结合杂志,2016,11(5):610-614.
[17] 郭震浪,苏振宁,王正飞,等. 半夏泻心汤加减治疗反流性食管炎疗效的Meta分析[J]. 中国实验方剂学杂志,2015,21(24):219-224.
[18] 林三仁,许国铭,胡品津,等. 中国胃食管反流病共识意见[J]. 胃肠病学,2007(4):233-239.
[19] 郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京:中国医药科技出版社,2002:05.
[20] 高望望. 半夏泻心汤治疗胃食管反流病67例疗效观察[J]. 中国中医急症,2010,19(2):212-213.
[21] 杨增文. 半夏泻心汤治疗老年反流性食管炎[J]. 中国中医药咨讯,2010,2(15):246.
[22] 叶凡. 半夏泻心汤加味治疗胃食管反流病56例[J]. 中国中医药现代远程教育,2011,9(3):92-93.
[23] 陈新江. 半夏泻心汤加减对胃食管反流病的观察[J]. 海峡药学,2012,24(11):133-134.
[24] 张官霖. 半夏泻心汤加减对胃食管反流病的观察[J]. 医药前沿,2012,2(7):342-343.
[25] 陈霞. 半夏泻心汤治疗58例胃食管反流病临床疗效评价[J]. 中医临床研究,2013,5(18):32-33.
[26] 周君丰. 半夏泻心汤治疗老年反流性食管炎30例[J]. 中医临床研究,2013,5(17):92-93.
[27] 郭凤翔. 半夏泻心汤加味治疗肝胃郁热型反流性食管炎的疗效观察[J]. 中国医药指南,2014,12(32):276-277.
[28] 陈军. 半夏泻心汤用于治疗反流性食道炎的效果评价[J]. 中国卫生标准管理,2016,7(36):120-122.
[29] 李琳,万强. 半夏泻心汤加减治疗反流性食管炎32例临床观察[J]. 黑龙江中医药,2016,45(3):19-20.
[30] 刘超,查锐. 半夏泻心汤治疗胃食管反流病的疗效观察[J]. 中国保健营养,2017,27(33):394.
[31] 黄墩煌,吴耀南,陈一斌,等. 半夏泻心汤化裁治疗寒热错杂型胃食管反流病41例临床观察[J]. 中医药通报,2018,17(3):57-59.
[32] 汤瑞珠,傅晓芸,梁少琴,等. 半夏泻心汤治疗寒热错杂型反流性食管炎疗效分析[J]. 现代医院,2018,18(6):910-912.
[33] 刘晓霓,金秀东,李月珍,等. 半夏泻心汤对反流性食管炎大鼠胃酸、胆汁酸和CGRP的影响[J]. 放射免疫学杂志,2008,21(4):312-314.
[34] 蒋锋利,王淑艳,李丽娜,等. 半夏泻心汤及其拆方对胃肠平滑肌细胞增殖的影响[J]. 辽宁中医杂志,2015,42(8):1540-1542.
[35] 童荣生,李晋奇,彭成. 半夏泻心汤调节胃肠运动的实验研究进展[J]. 中医药学报,2009,37(5):108-109.
[36] 张吉仲,李利民,黄利,等. 半夏泻心汤及其拆方对脾虚大鼠胃泌素和生长抑素的影响[J]. 中药药理与临床,2013,29(1):15-17.
[37] 刘晓霓,金秀东,李月珍,等. 半夏泻心汤对食管炎大鼠食管平滑肌收缩调控蛋白基因和细胞内游离钙的影响[J]. 中国实验方剂学杂志,2008,14(11):60-63.

备注/Memo

备注/Memo:
收稿日期: 2020 - 09- 29
基金项目: 国家自然科学基金面上项目(81973753) 第一作者简介: 俞赟丰(1997-),男,在读硕士研究生,研究方向:中医脾胃病诊疗研究。?/div>
?通信作者: 简维雄,E-mail:daxiong20001977@163.com
更新日期/Last Update: 1900-01-01